0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Beyond 'Abortion': RU-486 and the Needs of the Crisis Constituency

William Regelson, MD; Roger Loria, PhD; Mohammed Kalimi, PhD
JAMA. 1990;264(8):1026-1027. doi:10.1001/jama.1990.03450080112042.
Text Size: A A A
Published online

FOR THE first time, the medical needs of patients are being thwarted by a political and economic battle involving the "unborn." The threat of boycott by the antiabortion advocates is blocking or delaying the availability of RU-486 (mifepristone) as a drug of proven or potential value in Cushing's disease, meningioma, and breast cancer. As RU-486 poses no religious or moral issue in patients who are not pregnant, have no intention of getting pregnant, or are incapable of pregnancy, it may be concluded that the drug ban self-imposed by Hoechst-Roussel because of the issue of abortion and contraception should be lifted from studies of its medical application.

RU-486 ([11β(4-dimethyl-amino phenyl)]17β hydroxy[17α prop-1-ynyl]estra-4,9-dien-3-one), or mifepristone (originally named RU38486), is best known as an antiprogestin abortifacient or contraceptive,1-3 but its clinical potential extends beyond this. Apart from its antiprogesterone effects, the focal action of this drug as a blocking agent to corticosteroid

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();